Received Apr 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
adjuvant portion of the Shingrix vaccine was administered; adjuvant portion of the Shingrix vaccine was administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: adjuvant portion of the Shingrix vaccine was administered) and inappropriate dose of vaccine administered (Verbatim: adjuvant portion of the Shingrix vaccine was administered). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date: 14-APR-2025 The pharmacy assistant reported that the adjuvant portion of the Shingrix vaccine was administered to the patient which led to, Inappropriate preparation of medication and Inappropriate dose of vaccine administered. The reporter mentioned that the vaccination date, batch number and expiry date were unknown. This case had been link with US2025AMR046764, reported by the same reporter.; Sender's Comments: US-GSK-US2025AMR046764:Original Case : US2025AMR046764